Lucira Health, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Erik T. Engelson
- Full Time Employees
- 221
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1412 62nd Street EmeryVille CA United States of America 94608
- IPO Date
- Feb 4, 2021
- CIK
- 0001652724
- Website
- lucirahealth.com
- Similar Companies
- Business
- Lucira Health, Inc. (LHDX) develops and commercializes at-home molecular diagnostic test kits for infectious diseases, including the LUCIRA COVID-19 All-In-One Test Kit and COVID-19 & Flu combination test; it offers disposable diagnostic hardware that pairs with smartphones for rapid, lab-quality analysis of bodily fluids such as nasal swabs or saliva. The company, founded in 2013 and formerly known as Diassess Inc., is headquartered in Emeryville, California, and previously operated primarily in the United States with partnerships including manufacturing agreements with Jabil Inc. and a patent license with Eiken Chemical Co., Ltd. In 2023, Lucira filed for Chapter 11 bankruptcy protection in February, pursued a strategic asset sale process, and had substantially all of its assets acquired by Pfizer Inc. for $36.4 million in an April bankruptcy auction approved by the U.S. Bankruptcy Court for the District of Delaware; Pfizer subsequently managed the Lucira COVID-19 and flu test products, which faced FDA Emergency Use Authorization revocations in 2025 amid product discontinuation plans.
Why Is Lucira Health (LHDX) Stock Down 14% Today?
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Penny Stocks: The Importance of Liquidity and Volume
Penny Stocks To Buy Now? 7 Under $5 To Watch Before Next Week
Lucira Health shares rise more than 300% on FDA authorization of at-home combination COVID-19 and flu test
Why Is Lucira Health (LHDX) Stock Up 237% Today?
Lucira stock more than doubles after hours on FDA OK for COVID-19, flu test
Why Is Lucira Health (LHDX) Stock Down 34% Today?
5 Big Winners as Wall Street Wraps Up Strong January Gains
Biggest Penny Stocks Trading Mistakes to Avoid in 2023
Why Lucira Health (LHDX) Stock Up 400% Today?
Lucira Health, Inc. (LHDX) Q3 2022 Earnings Call Transcript
Lucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q2 2022 Results - Earnings Call Transcript
Lucira Health to Announce Second Quarter 2022 Financial Results
Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q1 2022 Results - Earnings Call Transcript
Lucira Health to Announce First Quarter 2022 Financial Results
Grab Market Momentum With 5 Top Rising P/E Stocks
Looking for a Growth Stock? Why It is Time to Focus on Lucira Health (LHDX)
Lucira Health, Inc. (LHDX) CEO Erik Engelson on Q4 2021 Results - Earnings Call Transcript